ADAG Stock Summary and Trading Ideas (Adagene - Ads Each Representing 1.25 | NASDAQ:ADAG)

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Adagene - Ads Each Representing 1.25 trades on the NASDAQ stock market under the symbol ADAG.

As of August 18, 2026, ADAG stock price climbed to $4.05 with 324,657 million shares trading.

ADAG has a beta of 0.30, meaning it tends to be less sensitive to market movements. ADAG has a correlation of 0.00 to the broad based SPY ETF.

ADAG has a market cap of $267.59 million. This is considered a Small Cap stock.

In the last 3 years, ADAG traded as high as $4.85 and as low as $1.10.

The top ETF exchange traded funds that ADAG belongs to (by Net Assets): PGJ.

ADAG has outperformed the market in the last year with a price return of +139.6% while the SPY ETF gained +20.4%. ADAG has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +15.7% and +11.6%, respectively, while the SPY returned +4.1% and +1.3%, respectively.

ADAG support price is $3.59 and resistance is $4.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADAG shares will trade within this expected range on the day.